KOA SHOJI HOLDINGS

What KOA SHOJI HOLDINGS does

KOA SHOJI HOLDINGS CO., LTD. (TSE Prime Market, ticker 9273.T) is a Japanese pharmaceutical holding company headquartered in Yokohama, Kanagawa, operating through a holding company structure established in January 2015. The group comprises three core subsidiaries — KOA SHOJI (pharmaceutical trading and import/export), KOA ISEI (generic-drug manufacturing, including the high-potency sterile Ube Plant), and KOA BIO TECH (biotechnology) — alongside acquired entities KOA Bayer Pharma, KOA Eisai, and KOA Sawai Pharmaceutical. The group functions as a vertically integrated pharmaceutical value chain covering wholesale distribution (卸売機能) and contract development and manufacturing (CDMO / メーカー機能), with manufacturing positioned as the primary growth lever.

The company's underlying capabilities center on pharmaceutical manufacturing and quality control, including high-potency active pharmaceutical ingredient (API) production in sterile, contamination-free environments, supported by an in-house pharmaceutical analysis center. Core products include pharmaceutical wholesale distribution to healthcare providers and pharmacies, and contract CDMO services spanning R&D through commercial-scale production for pharmaceutical companies. The company markets a "Virtual Factory" capability that demonstrates manufacturing operations and supports customer confidence in production standards. Customers are segmented into two primary groups: healthcare providers and pharmacy networks receiving wholesale supply, and pharmaceutical companies requiring OEM/CDMO services — particularly those needing high-potency or sterile drug manufacturing capacity.

Commercially, the group operates a sales-led B2B model targeting both customer segments through established pharmaceutical distribution channels and direct manufacturing relationships. Its mid-term management plan targets ¥80 billion in consolidated operating profit by 2030, anchored on CDMO expansion, with a second sterile manufacturing plant scheduled for completion in July 2027. The group is solely Japan-domiciled, with no disclosed international operations, and total headcount of 304 employees as of the June 2025 ESG reporting period.

Name

KOA SHOJI HOLDINGS

Legal name

KOA SHOJI HOLDINGS CO., LTD.

Website

https://koashoji-hd.com

Company type

Public

Founded year

1991

Operating status

Operating

Headcount range

251–500 employees

Short description

KOA SHOJI HOLDINGS (9273.T) is a Japanese pharmaceutical holding company operating KOA SHOJI (trading), KOA ISEI (generic-drug manufacturing and CDMO), and KOA BIO TECH (biotech), serving Japanese healthcare providers, pharmacies, and pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution and Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Pharmaceutical wholesale
• Pharmaceutical manufacturing
• Contract drug manufacturing
• Generic drug production
• Pharmaceutical distribution

Headquarters

HQ city

Yokohama-shi

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Wholesale (卸売機能): Wholesale distribution of pharmaceutical products to healthcare providers and pharmacies
2. Pharmaceutical Manufacturing (メーカー機能): Contract development and manufacturing organization (CDMO) services for pharmaceutical products; proprietary drug formulation and mass production capabilities including second sterile manufacturing plant planned for July 2027

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

KOA SHOJI HOLDINGS operates a vertically integrated pharmaceutical business through three subsidiaries: KOA SHOJI performs pharmaceutical wholesale and import/export trading; KOA ISEI manufactures generic drugs and provides CDMO services including high-potency sterile drug production; and KOA BIO TECH develops biotechnology products. The group supplies healthcare providers, pharmacies, and pharmaceutical manufacturers across Japan.

Product overview

KOA SHOJI HOLDINGS is a pharmaceutical holding company comprising three core business units: KOA SHOJI (pharmaceutical trading), KOA ISEI (pharmaceutical manufacturing), and KOA BIO TECH (biotechnology). The group operates a comprehensive pharmaceutical value chain from import/export trading to manufacturing and CDMO services, specializing in generic drug development and production.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Wholesale Distribution (KOA SHOJI)
• Generic Drug Manufacturing (KOA ISEI)
• Pharmaceutical CDMO Services
• Biotechnology Products (KOA BIO TECH)

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves11 records

Expansion highlights4 records

Direct peers

• Alfresa Holdings: Major Japanese pharmaceutical wholesaler operating via a holding company, distributing to hospitals, clinics, and pharmacies. Direct competitor to KOA's wholesale segment with overlapping channels.
• Medipal Holdings: Japan's largest pharmaceutical wholesaler with a holding company structure. Comparable to KOA's wholesale function and TSE Prime listing, with broader scale and product breadth.
• Suzuken: One of Japan's top pharmaceutical wholesalers with a hybrid model including manufacturing through its group. Closely comparable to KOA's integrated wholesale + manufacturing structure.
• Sawai Group Holdings: One of Japan's largest generic pharmaceutical manufacturers. Comparable to KOA ISEI's generic drug manufacturing business, with much larger scale.
• Toho Holdings: Japanese pharmaceutical wholesale holding company serving hospitals, clinics, and pharmacies nationwide. Comparable to KOA's wholesale business in customer base and channel model.
• CMIC Holdings: Japanese CRO/CDMO offering contract development and manufacturing services. Closely comparable to KOA's CDMO growth driver, though CMIC is more CRO-focused.
• Nichi-Iko Pharmaceutical: Major Japanese generic drug manufacturer with CDMO capabilities. Comparable to KOA's generic manufacturing and high-potency drug formulation focus.

Broad incumbents

• Takeda Pharmaceutical: Japan's largest pharma company with significant CDMO partnerships and contract manufacturing spend. Indirectly comparable as a potential CDMO customer for KOA.

Regional players

• KYORIN Pharmaceutical: Japanese specialty pharmaceutical company with contract manufacturing relationships. Comparable in domestic pharma specialty/generic overlap with KOA's CDMO business.

Emerging players

• Daiichi Fine Chemical: Japanese pharmaceutical CDMO specializing in sterile injectables and high-potency APIs. Closely comparable to KOA's emerging CDMO focus on sterile and high-potency manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KOA SHOJI HOLDINGS